PulmonxvsMerck & Company

LUNG and MRK stock compared: price, dividend, valuation and results, from SEC filings.

LUNG

Pulmonx Corporation

$2.80

Value $118M

-2.10%
LUNG's page

MRK

Merck & Company, Inc.

$144.46

Value $357B

-2.23%
MRK's page

Pulmonx (LUNG) has a market value of $118M and Merck & Company (MRK) $357B. Over the last year, with dividends, LUNG moved +87.9% and MRK +60.0%. Dividend yield: LUNG none, MRK 2.35%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LUNG$118M

    MRK$357B

    MRK is 3,020 times LUNG

  • Revenue, 12 months

    LUNG$89M

    MRK$67.4B

    MRK is 759 times LUNG

  • Net income, 12 months

    LUNG-$43M

    MRK$2.5B

  • Operating margin

    LUNG-44.4%

    MRK–

  • ROIC

    LUNG-37.0%

    MRK3.9%

    40.9 points apart

  • P/E

    LUNG–

    MRK145.6

  • Dividend yield

    LUNG0.0%

    MRK2.4%

    2.4 points apart

  • 5-year return

    LUNG-92.7%

    MRK+101.1%

    193.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LUNG-92.7%

MRK+101.1%

010020020222023202420252026
Returns by period
PeriodLUNGWith dividendsMRKWith dividends
1 year since November 14, 2025+87.9%Price +87.9%+60.0%Price +55.5%
3 years since November 16, 2023-74.2%-36.3% a yearPrice -74.2%+55.2%+15.8% a yearPrice +41.6%
5 years since November 15, 2021-92.7%-40.7% a yearPrice -92.7%+101.1%+15.0% a yearPrice +72.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LUNGPulmonxMRKMerck & Company

Valuation

LUNGMRK
Valuation
Price$2.80$144.46
Market value$118M$357B
Enterprise value (EV)–$401B
P/E–145.6
P/E, 5-year median–14.8
P/B3.58.0
EV/EBIT–84.3
Free cash flow yield–4.1%

Results and growth

LUNGMRK
Results and growth
Revenue, 12 months$89M$67.4B
Net income, 12 months-$43M$2.5B
Free cash flow, 12 months-$26M$14.7B
Earnings per share, 12 months-$1.01$0.98
Revenue growth, year on year8.0%1.3%
Revenue growth a year, past+22.6%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

LUNGMRK
Margins and returns on capital
Gross margin77.4%71.8%
Operating margin-44.4%–
Net margin-47.9%3.6%
ROIC-37.0%3.9%
ROE-91.2%5.2%

Balance sheet

LUNGMRK
Balance sheet
Cash$53M$9.7B
Total debt–$53.8B
Net debt / EBITDA–5.7
Interest cover-9.4×2.4×

Dividends and buybacks

LUNGMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LUNG or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Pulmonx or Merck & Company?

By market value, Merck & Company ($357B) is about 3,020.0 times Pulmonx ($118M), at today's prices.

How did LUNG and MRK stock do over the last 5 years?

Since November 15, 2021, LUNG's price moved -92.7% and MRK's +72.6%. With dividends: LUNG -92.7% (-40.7% a year), MRK +101.1% (+15.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, LUNG or MRK?

The dividend yield at today's price is none for Pulmonx and 2.35% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Pulmonx or Merck & Company?

Over the last twelve months, the net margin was -47.9% for Pulmonx and 3.6% for Merck & Company, and the operating margin -44.4% and –. Revenue was $89M and $67.4B.

Which is the better investment, Pulmonx or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.